EDAP TMS S.A.

EDAP TMS S.A. (NASDAQ: EDAP) is a urology-focused company that designs, manufactures, promotes, and distributes minimally invasive medical devices using proprietary ultrasound technology.

Key Highlights

• The company reported a growth of 0.07% in total revenue to EUR 9.44 million in Q3FY21 (ended September 30, 2021) compared to EUR 9.43 million in Q3FY20.
• Net loss for Q3FY21 increased to EUR 1.02 million from EUR 1.00 million reported in Q3FY20.
• On September 28, 2021, The Focal One high intensity focused ultrasound (HIFU) technology from EDAP has been acquired by University of Washington (UW) Medicine for the precise ablation of prostate tissue. UW Medicine will use Focal One to implement the focal therapy programme at its UW Medical Center location.
• Negative Net Margin of 10.8% whereas Peer’s Median stood at 6.2%.
• Its Debt/Equity ratio as of Q3FY21 was 0.14x.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 4.52 to USD 10.68.
• EDAP's share price has decreased 30.13% in the past nine months and increased 22.86% in twelve months.

Technical Price Chart (as of December 17, 2021). Analysis by Kalkine

Conclusion: Considering the movement in the stock price in the past twelve months, flat top and bottom-line performance, current trading levels, and associated risks, we recommend a "Watch" rating on the stock at the current price of USD 5.75, down 1.71% as of December 17, 2021, 12:20 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is an immunology company specializing in developing novel drugs for inflammation, fibrosis, metabolism, and immuno-oncology.

Key Highlights

• The company reported a massive decline of 92.09% in revenue to USD 97.32 thousand in Q3FY21 (ended September 30, 2021) compared to USD 1.23 million in Q3FY20.
• Net loss for Q3FY21 reduced to USD 2.18 million from USD 34.90 million reported in Q3FY20.
• On December 07, 2021, CRBP appointed Dr. Rachael Brake as Chief Scientific Officer. Dr. Brake joins the Company following the recent acquisition of monoclonal antibodies that suppress TGF activation, building on CRBP's commitment to immuno-oncology.
• Negative ROE of 2.8% as of Q3FY21.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 0.63 to USD 4.00.
• CRBP's share price has decreased 66.67% and 68.06% in the past six and nine months, respectively.

Technical Price Chart (as of December 16, 2021). Analysis by Kalkine

Conclusion: Considering the significant correction in the stock price in the past nine months, reduction in net losses, current trading levels, and associated risks, we recommend a "Watch" rating on the stock at the closing price of USD 0.69, up 0.83% as of December 16, 2021.

*The reference data in this report has been partly sourced from REFINITIV.